Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
COR last changed hands at $312.24 (down 0.01%). At $59.58B, Cencora is ranked #270 by size among the 300 stocks on BeStock.
Over the past 52 weeks it has traded between $243.78 and $375.33, so it sits 16.8% below the top of that range. Holders are ahead 2.0% over twelve months, and up 10.0% across the last three months.
On the chart it has slipped under both the 50-day ($317.12) and 200-day ($318.37) moving averages; RSI is 50, and the last 30 sessions moved at roughly 28% annualized volatility.
For the quarter ended Jun 2026 it reported $84.75B in revenue, up 5.1% from a year earlier, with $776.67M of net profit (a 0.8% margin).
Buyers are paying 23.2 times trailing earnings, 6% below its five-year average of 24.7.
12 analysts follow the stock and the average call is "buy". The mean target, $373.10, sits 19.5% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Cencora distributes prescription drugs to pharmacies, hospitals and clinics, and provides services to drugmakers.
What tends to move it. Prescription volume, specialty drug growth and thin distribution margins are the story. It is a steady, low-drama business.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -3.3% | Bearish |
| Price vs 50-day average | -1.5% | Bearish |
| Price vs 200-day average | -1.9% | Bearish |
| 50-day vs 200-day | 50d below 200d | Bearish |
| RSI (14) | 49.8 | Bearish |
| MACD (12,26,9) | -0.72 | Bearish |
| Bollinger band position | 15% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 1:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q3, ended Jun 2026
Quarter 2026/Q3
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Around its usual level · 51st percentile, 5-year average 24.7x
#1799 of 2977 stocks by PE (1 = cheapest)
Near the bottom of its 5-year range · 16th percentile, 5-year average 73.7x
#5096 of 5304 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 84th percentile, 5-year average 0.2x
#330 of 5143 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$12.69M (9 inflow days, 11 outflow days).
Across the full calendar years shown, the annual payout shrank by roughly 10.8% a year.
$312.24 is the latest print for COR, a move of -0.01% against yesterday's close of $312.28. Today's low and high so far: $310.89 and $316.61.
Equity value comes to $59.58B at the current price. By that measure it is number 270 of the 300 names in our coverage.
Buyers pay 23.2 times the last twelve months of profit (EPS $7.96). Averaged over five years the multiple has been 24.7, and today's level ranks in the 51st percentile of its own history.
The year's floor is $243.78 and the ceiling $375.33. Shares are 16.8% away from that ceiling.
It does. Payouts over the past twelve months work out to a 0.75% yield; the latest ex-dividend date was August 14, 2026.
Of 12 analysts, 75% say buy, 25% hold and 0% sell. Price targets average $373.10, with the most cautious at $330.00 and the most optimistic at $430.00.
Cencora distributes prescription drugs to pharmacies, hospitals and clinics, and provides services to drugmakers.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.